KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Research & Development (2019 - 2025)

Historic Research & Development for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $31.0 million.

  • GoodRx Holdings' Research & Development rose 289.66% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.8 million, marking a year-over-year decrease of 17.41%. This contributed to the annual value of $123.7 million for FY2024, which is 889.82% down from last year.
  • GoodRx Holdings' Research & Development amounted to $31.0 million in Q3 2025, which was up 289.66% from $29.9 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Research & Development registered a high of $39.6 million during Q3 2023, and its lowest value of $26.2 million during Q1 2021.
  • Over the past 5 years, GoodRx Holdings' median Research & Development value was $31.7 million (recorded in 2024), while the average stood at $32.7 million.
  • As far as peak fluctuations go, GoodRx Holdings' Research & Development soared by 15336.56% in 2021, and later tumbled by 2391.25% in 2024.
  • Quarter analysis of 5 years shows GoodRx Holdings' Research & Development stood at $35.1 million in 2021, then grew by 4.88% to $36.8 million in 2022, then dropped by 12.89% to $32.0 million in 2023, then fell by 0.91% to $31.7 million in 2024, then fell by 2.29% to $31.0 million in 2025.
  • Its Research & Development was $31.0 million in Q3 2025, compared to $29.9 million in Q2 2025 and $31.1 million in Q1 2025.